Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gradient Denervation Technologies

Request full access

Developing a novel endovascular, catheter-based technology to treat pulmonary hypertension

Paris, FranceFounded 2019Biotech & Life Sciences

About Gradient Denervation Technologies

Gradient Denervation Technologies is a Paris-based medical device startup that focuses on the development of a unique, minimally invasive ultrasound-based catheter. This device is designed to treat heart failure patients who also suffer from pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. The company's innovative therapeutic approach aims to improve cardiovascular health.

The company's target market includes patients suffering from Group 2 pulmonary hypertension, which is heart failure accompanied by high pulmonary vascular resistance. The company's business model revolves around the development, clinical testing, and eventual commercialization of its novel catheter-based system.

Gradient Denervation Technologies recently closed a €14m Series A funding round led by Sabadell Asabys, with participation from Thuja Capital and founding investor Sofinnova Partners. These funds will be used to advance the clinical development of the company's device.

The company has already enrolled its first patient in a first-in-human clinical study, marking a significant milestone in its journey. The company is led by CEO Martin Grasse, a veteran with over 15 years in the medical device industry.

In summary, Gradient Denervation Technologies is a promising startup in the medical device sector, with a focus on improving the lives of heart failure patients with associated pulmonary hypertension. Its innovative, minimally invasive device has the potential to revolutionize treatment in this area.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
1
Dealroom signal
78.0/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Cardiology and cardiovascular, Catheters, Pulmonary, European Health Catapult (EIT Health), European Health Catapult 2020 (EIT Health), EIT Health
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Sep 2023 $15M $62M Sofinnova Partners · Thuja Capital · Asabys Partners ↗
SUPPORT PROGRAM✓Other financing Jun 2022 $0 — MedTech Innovator ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Gradient Denervation Technologies website traffic

Latest recorded traffic for Gradient Denervation Technologies is 540 monthly website visits, down 25% over the last three months. Gradient Denervation Technologies's team grew 20% over the past year.

Latest monthly visits540 3-month web change-25% 1-year team growth+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Gradient Denervation Technologies in the Paris ecosystem

Live from Dealroom

The Gradient Denervation Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A2 investors entered at this stage

  • Asabys Partners
  • Thuja Capital

Other known investors2 additional known investors

  • EIT Health
  • MedTech Innovator
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Gradient Denervation Technologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.